BRAF and thyroid gland carcinoma: The development of a thyroid cancer model utilizing CRISPR-Cas9 technology revealed that the upregulation of TIMP1, MMP9, and CD44 in genetically modified thyroid progenitor cells facilitates tumor proliferation, while the increased expression of KISS1 and KISS1R in cells harboring BRAF, NRAS, or TP53 mutations correlates with the likelihood of invasion and metastasis.